IBDEI0LN ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10263,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10263,1,3,0)
 ;;=3^Oth Ill-Defined Eye D/O
 ;;^UTILITY(U,$J,358.3,10263,1,4,0)
 ;;=4^379.99
 ;;^UTILITY(U,$J,358.3,10263,2)
 ;;=^269335
 ;;^UTILITY(U,$J,358.3,10264,0)
 ;;=555.9^^44^562^95
 ;;^UTILITY(U,$J,358.3,10264,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10264,1,3,0)
 ;;=3^Regional Enteritis,Unspec
 ;;^UTILITY(U,$J,358.3,10264,1,4,0)
 ;;=4^555.9
 ;;^UTILITY(U,$J,358.3,10264,2)
 ;;=^29356
 ;;^UTILITY(U,$J,358.3,10265,0)
 ;;=696.1^^44^562^93
 ;;^UTILITY(U,$J,358.3,10265,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10265,1,3,0)
 ;;=3^Psoriasis
 ;;^UTILITY(U,$J,358.3,10265,1,4,0)
 ;;=4^696.1
 ;;^UTILITY(U,$J,358.3,10265,2)
 ;;=^271917
 ;;^UTILITY(U,$J,358.3,10266,0)
 ;;=709.2^^44^562^39
 ;;^UTILITY(U,$J,358.3,10266,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10266,1,3,0)
 ;;=3^Facial Scar
 ;;^UTILITY(U,$J,358.3,10266,1,4,0)
 ;;=4^709.2
 ;;^UTILITY(U,$J,358.3,10266,2)
 ;;=^108131
 ;;^UTILITY(U,$J,358.3,10267,0)
 ;;=710.0^^44^562^60
 ;;^UTILITY(U,$J,358.3,10267,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10267,1,3,0)
 ;;=3^Lupus,Systemic Erythmatosis
 ;;^UTILITY(U,$J,358.3,10267,1,4,0)
 ;;=4^710.0
 ;;^UTILITY(U,$J,358.3,10267,2)
 ;;=^72159
 ;;^UTILITY(U,$J,358.3,10268,0)
 ;;=710.9^^44^562^10
 ;;^UTILITY(U,$J,358.3,10268,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10268,1,3,0)
 ;;=3^Collagen Disease NOS
 ;;^UTILITY(U,$J,358.3,10268,1,4,0)
 ;;=4^710.9
 ;;^UTILITY(U,$J,358.3,10268,2)
 ;;=^123811
 ;;^UTILITY(U,$J,358.3,10269,0)
 ;;=714.0^^44^562^98
 ;;^UTILITY(U,$J,358.3,10269,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10269,1,3,0)
 ;;=3^Rheumatoid Arthritis
 ;;^UTILITY(U,$J,358.3,10269,1,4,0)
 ;;=4^714.0
 ;;^UTILITY(U,$J,358.3,10269,2)
 ;;=^10473
 ;;^UTILITY(U,$J,358.3,10270,0)
 ;;=714.30^^44^562^99
 ;;^UTILITY(U,$J,358.3,10270,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10270,1,3,0)
 ;;=3^Rheumatoid Arthritis,Juvenile
 ;;^UTILITY(U,$J,358.3,10270,1,4,0)
 ;;=4^714.30
 ;;^UTILITY(U,$J,358.3,10270,2)
 ;;=^24424
 ;;^UTILITY(U,$J,358.3,10271,0)
 ;;=744.89^^44^562^38
 ;;^UTILITY(U,$J,358.3,10271,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10271,1,3,0)
 ;;=3^Face/Neck Anom NEC,Congenital
 ;;^UTILITY(U,$J,358.3,10271,1,4,0)
 ;;=4^744.89
 ;;^UTILITY(U,$J,358.3,10271,2)
 ;;=^272875
 ;;^UTILITY(U,$J,358.3,10272,0)
 ;;=759.6^^44^562^116
 ;;^UTILITY(U,$J,358.3,10272,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10272,1,3,0)
 ;;=3^Von-Hippel Lindau Disease
 ;;^UTILITY(U,$J,358.3,10272,1,4,0)
 ;;=4^759.6
 ;;^UTILITY(U,$J,358.3,10272,2)
 ;;=^87431
 ;;^UTILITY(U,$J,358.3,10273,0)
 ;;=759.82^^44^562^62
 ;;^UTILITY(U,$J,358.3,10273,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10273,1,3,0)
 ;;=3^Marfan Syndrome
 ;;^UTILITY(U,$J,358.3,10273,1,4,0)
 ;;=4^759.82
 ;;^UTILITY(U,$J,358.3,10273,2)
 ;;=^74034
 ;;^UTILITY(U,$J,358.3,10274,0)
 ;;=802.4^^44^562^36
 ;;^UTILITY(U,$J,358.3,10274,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10274,1,3,0)
 ;;=3^FX Malar/Maxillary Bones,Closed
 ;;^UTILITY(U,$J,358.3,10274,1,4,0)
 ;;=4^802.4
 ;;^UTILITY(U,$J,358.3,10274,2)
 ;;=^25312
 ;;^UTILITY(U,$J,358.3,10275,0)
 ;;=870.1^^44^562^53
 ;;^UTILITY(U,$J,358.3,10275,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10275,1,3,0)
 ;;=3^Laceration Full Thickness
 ;;^UTILITY(U,$J,358.3,10275,1,4,0)
 ;;=4^870.1
 ;;^UTILITY(U,$J,358.3,10275,2)
 ;;=^274880
 ;;^UTILITY(U,$J,358.3,10276,0)
 ;;=870.2^^44^562^34
 ;;^UTILITY(U,$J,358.3,10276,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10276,1,3,0)
 ;;=3^Eyelid Laceration Involving Lacrimal
 ;;^UTILITY(U,$J,358.3,10276,1,4,0)
 ;;=4^870.2
 ;;
 ;;$END ROU IBDEI0LN
